[PECULIARITIES IN VIRUS EXCRETION AND ANTIBODY FORMATION AFTER ADMINISTRATION OF A "BALANCED" LIVE VACCINE MIXTURE OF POLIOVIRUS TYPES I AND II].
D000917:Antibody Formation; D035843:Biomedical Research; D030015:Enterovirus C, Human; D006801:Humans; D007223:Infant; D017955:Poliovirus; D011055:Poliovirus Vaccine, Oral; D023321:Poliovirus Vaccines; D014556:Urine; D014613:Vaccines, Attenuated
D011055:Poliovirus Vaccine, Oral; D023321:Poliovirus Vaccines; D014613:Vaccines, Attenuated
ANTIBODY FORMATION; CLINICAL RESEARCH; INFANT; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; URINE
BESONDERHEITEN BEI DER VIRUSAUSSCHEIDUNG UND ANTIKOERPERBILDUNG NACH VERABREICHUNG EINER "AUSGEWOGENEN" POLIOVIRUS TYP I UND II-LEBENDIMPFSTOFFMISCHUNG.